A Study of AL102 in Patients With Progressing Desmoid Tumors

Prior treatment

• Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ≤7 days prior to administration of IP such as known active infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) at Screening.
• Any treatments for desmoid tumors within 4 weeks prior to first dose of investigational therapy; subject must have recovered from therapy related toxicity to \< CTCAE Grade 2 or clinical baseline. Therapy includes:
  • Locoregional tumor directed therapies such as major surgery, radiation, radiofrequency ablation, or cryosurgery
  • Systemic therapy including chemotherapy, biologic (anti-neoplastic agent, antibodies), TKIs (e.g., sorafenib, pazopanib, imatinib), hormonal therapy, or investigational therapy

Other illness

• Diagnosed with a malignancy in the past 2 years with some exceptions.
• Current or recent (within 2 months of IP administration) GI disease or disorders that increase the risk of diarrhea, such as inflammatory bowel disease and Crohn's disease.

Lab values

• Myocardial infarction within 6 months prior to enrollment, greater than Class 1 angina pectoris, or has New York Heart Association (NYHA) Class III or IV heart failure, symptomatic ventricular arrhythmias, sustained ventricular tachycardia, Torsade's de Pointes (TdP), the long QT syndrome, pacemaker dependence, or electrocardiographic evidence of acute ischemia.
• Unstable or severe uncontrolled medical condition (e.g., unstable cardiac or pulmonary function or uncontrolled diabetes) or any important medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the risk to the subject associated with his or her participation in the study.
• Abnormal organ and marrow function at Screening defined as:
  • Neutrophils \<1000/mm3,
  • Platelet count \<100,000/mm3,
  • Hemoglobin \<9 g/dL,
  • Total bilirubin \>1.5x upper limit of normal (ULN) (except known Gilbert's syndrome),
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \>2.5x ULN,
  • Serum creatinine \> ULN and creatinine clearance (CrCl) \<60 mL/min (calculation of CrCl will be based on acceptable institution standard)
  • Uncontrolled triglyceride ≥Grade 2 elevations per common terminology criteria for adverse events (CTCAE) v5.0 (\>300 mg/dL or \>3.42 mmol/L).
• ECG Exclusions
  • Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥450 msec.
  • QRS duration \> 110 ms
  • PR interval \> 240 ms
  • Marked ST-T wave abnormalities which would make it difficult to measure the QT interval
• Unstable or severe uncontrolled medical condition (e.g., unstable cardiac or pulmonary function or uncontrolled diabetes) or any important medical illness, abnormal ECG or abnormal laboratory finding that would, in the investigator's judgment, increase the risk to the participant associated with his or her participation in the study.
• Any participant with an ongoing TEAE (including abnormal laboratory results) from Part A or Part B that requires discontinuation from the study, will not be eligible to enter the open-label extension.

Other

• Pregnant or breastfeeding or expecting to conceive children within the projected duration of the study.
• Eastern Cooperative Oncology Group (ECOG) performance status ≥2
• Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP
  • OLE Key Exclusion Criteria:
• Breastfeeding or expecting to conceive children within the projected duration of the study.

• At least 18 years of age (inclusive) at the time of signing the informed consent form (ICF).
• Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent).
• Disease progression, assessed locally by the investigator, defined as having at least one of the following:
  • Unidimensional growth of desmoid tumor(s) by ≥10%, using the sum of the largest diameters of target lesion(s), within 18 months of the screening MRI
  • Having desmoid tumor-related pain that is not adequately controlled with nonopioid medication
• At least 1 measurable lesion amenable to volume measurements by MRI at screening
• One of the following:
  • Treatment naïve subjects for whom, in the opinion of the investigator, the IP is deemed appropriate, OR
  • Recurrent/refractory disease following at least one line of therapy (including surgery, radiation, or systemic therapy)
• Agrees to provide formalin-fixed paraffin embedded archival or fresh tumor tissue for re-confirmation of disease.
• Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed.
• ≥12 years of age (inclusive) and ≥ 40 kg at the time of signing the ICF.
• Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed by ≥ 20% as measured by RECIST v1.1 within 12 months of the screening visit scan.
• Evidence of measurable disease by CT/MRI scan. Measurable lesions are defined according to RECIST v1.1.
• Subject and/or legally authorized representative (i.e. parent/guardian) must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF.
• Minor subjects must be capable of giving written assent as appropriate per the applicable age (per local regulatory requirements).
  • OLE Key Inclusion Criteria:
  • 1\. One of the following:
• Participated in Part A (including MRI at Week 16) and were still on study at time that Part B/OLE dose selection was made, OR
• Participating in Part B and were noted to have radiographic progressive disease by BICR, OR
• Are on study treatment (placebo or varegacestat) after completion of Part B